ARTICLE | Company News
Regen, CheckPoint deal
March 17, 2017 7:10 PM UTC
Regen granted its CheckPoint Immunology Inc. subsidiary an exclusive, worldwide license to develop and commercialize nuclear receptor subfamily 2 group F member 6 (NR2F6; COUP-TFIII) technology for hu...
BCIQ Company Profiles
BCIQ Target Profiles
Nuclear receptor subfamily 2 group F member 6 (NR2F6) (COUP-TFIII)